To develop the PPZ series of small molecule pan-filovirus entry inhibitors through lead optimization, selection of a preclinical candidate, and IND-enabling preclinical studies.
Active Definitive Contract Awarded Last action
- Contract number
- 75N93023C00001
- Awardee
-
Microbiotix, Inc. UEI SCNKBDM341T1
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $8,795,790
Award facts
- Opportunity
-
- 2022 NIAID Omnibus Broad Agency Announcement Pre-Solicitation · BAA20221 · Posted Jan 4, 2022
- Contract value 62% obligated
-
- $8,795,790.00 Current, with exercised options
- $14,195,727.00 Potential, with all options
- Completion date 75% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 10 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Worcester, MA 01605, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $3,787,586 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $2,938,788 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $2,069,416 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a $14.2 million definitive contract to Microbiotix, Inc. for development of the PPZ series of small molecule pan-filovirus entry inhibitors through lead optimization, selection of a preclinical candidate, and IND-enabling preclinical studies, effective November 1, 2022.
The contract is structured as cost-plus-fixed-fee with an ultimate completion date of March 1, 2028. Place of performance is Worcester, MA. The originating Broad Agency Announcement, posted January 4, 2022, sought proposals for vaccine candidates, therapeutics, and diagnostics for biodefense, antimicrobial-resistant infections, and emerging infectious diseases, with individual contract values limited to base-period amounts not exceeding five years.
Government invoicing reflects a declining labor footprint: FY2023 recorded 3.2 FTEs across 6,712 contractor hours at $139.53 per hour; FY2024 declined to 1.3 FTEs across 2,619 contractor hours; FY2025 dropped to 0.9 FTEs. Microbiotix self-performed all reported work with no subcontractors.
Quick answers
Who was awarded contract 75N93023C00001?
75N93023C00001 was awarded to Microbiotix, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on November 1, 2022.
How much is contract 75N93023C00001 worth?
The government has obligated $8,795,790 on 75N93023C00001. Its potential value, with all options, is $14,195,727.
Was contract 75N93023C00001 competed?
The extent of competition for 75N93023C00001 was full and open competition. The government received 10 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award